Streetbeat News

Stock Prices

GEHC

GE HealthCare Technologies' stock is trading lower following the announcement of a secondary offering of 13 million shares of its common stock.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:08 am

SURG

SurgePays shares are trading lower following the announcement of disappointing Q4 financial results, which were below market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:06 am

BIRD

Allbirds shares are trading lower following the company's announcement of weak guidance for future performance.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:05 am

MINM

Minim shares have seen an uptick following the announcement of a definitive merger agreement with e2Companies. This strategic move could potentially enhance Minim's market position and offer new growth avenues.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:05 am

GHLD

Guild Holdings shares are trading lower following the announcement of worse-than-expected Q4 revenues.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:04 am

WOOF

Petco Health and Wellness (WOOF) reported Q4 adjusted earnings of $0.02 per share, meeting analyst estimates, but marking a 91.3% decrease from last year's $0.23. Quarterly sales reached $1.67 billion, exceeding the $1.62 billion estimate and showing a 6.08% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

WOW

WideOpenWest (NYSE:WOW) reported Q4 losses of $(0.54) per share, missing the $(0.01) estimate by 5300%, and a 260% decrease from last year. Sales were $168.80M, missing the $170.57M estimate by 1.04%, and a 6.48% decrease from last year.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

SWIM

Latham Group's shares are trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

IONS

Ionis Pharmaceuticals, Inc. announced positive results from a Phase 2 study of ION224, a treatment for metabolic dysfunction-associated steatohepatitis (MASH), meeting primary and important secondary endpoints.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am

MXCT

MaxCyte shares surged following the announcement of their Q4 financial results, which exceeded expectations. Additionally, the company provided positive guidance for FY24.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 11:03 am